LABORATORY MARKERS OF PERINATAL DISORDERS IN WOMEN WITH COVID-19

Introduction. There is insufficient data in the available literature on the association of laboratory changes in pregnant women with COVID-19, in particular coagulopathy indicators, with adverse pregnancy outcomes.The aim of the study is to identify potential laboratory markers of perinatal disorders in COVID-19 during pregnancy.Materials and methods. The comprehensive study included: 200 pregnant women who were hospitalized with COVID-19 during pregnancy (main group) and 50 patients who did not have COVID-19 during pregnancy (control group). The main group was divided into 2 subgroups: O1 – 50 women with adverse perinatal outcomes, O2 – 150 patients with a relatively favorable course of the gestational period.Complete blood count, biochemical indicators, and individual hemostasis parameters were taken into account.Study results. Potential risk factors for perinatal disorders in COVID-19 include anemia, thrombocytopenia, leukocytosis with increased rod-shaped neutrophils, increased liver transaminases, increased C-reactive protein, increased platelet aggregation, prothrombotic changes in hemostasis, in particular increased D-dimer, endothelial damage (increased von Willebrand factor). High activity of inflammatory processes in pregnant women with COVID-19 underlies systemic vasculitic changes and defects in blood coagulation processes, which cause damage to the maternal-fetal complex.Conclusions. It is important to monitor blood parameters in pregnant women with COVID-19 for timely detection of deterioration of the woman's condition and possible negative impact on perinatal outcomes.